Study S000516

Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study

ClinicalTrials.gov record

Registration

Registration: NCT07537088
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 468
Start: 2026-05
Primary completion: 2027-04
Lead sponsor: First Affiliated Hospital of Wannan Medical College
Conditions: T2DM (Type 2 Diabetes Mellitus); CKD - Chronic Kidney Disease
Interventions: DRUG:Dulaglutide; DRUG:SGLT2i; DRUG:Finerenone
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Urine Albumin-to-Creatinine Ratio（UACR） [Change in UACR from baseline at Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.